Items tagged with HIV coinfection
Health experts call for integrated approach to HIV and TB in Zimbabwe (post)
Zimbabwe is facing challenges in eliminating tuberculosis (TB) say health experts, who are calling for much greater integration of HIV and TB programmes within the healthcare system.
No advantage with early ART in TB patients with CD4 count above 220 (post)
Starting antiretroviral therapy (ART) 2 weeks after TB therapy began did not lower proportions of African patients who reached a composite endpoint including TB treatment failure, TB recurrence, and death, according to results of a randomized double-blind trial in people with a CD4 count above 220 cells/µL. The findings contrast with two earlier trials in which starting ART early in the course of TB therapy had marked clinical benefits in people with a CD4 count below 50 or 200 cells/µL.
Antiretroviral changes rare in TB patients enrolled in SAPiT Trial (post)
Among South Africans with HIV/TB coinfection, antiretroviral changes were rare during TB therapy when the initial regimen was efavirenz plus lamivudine and didanosine, according to analysis of 501 people in the SAPiT trial.
In Pictures: Myanmar patients in India (post)
A doddering healthcare system pushes many from Myanmar to cross the Indian border into the town Moreh in the northeastern state of Manipur, to seek testing and treatment. Most patients suffer from drug-resistant tuberculosis (TB) and are HIV positive.
India: Dosage of key drug for HIV+ too low to counter TB, reveals study (post)
CHENNAI: Experts may fret about overprescription of drugs for tuberculosis, but it has emerged that central health authorities' mandatory dosage of a key drug for HIV-infected patients with the disease is too low for it to be effective.
Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial (post)
Summary
First-ever TB/HIV networking zone announced for AIDS 2014 (post)
For the first time, the upcoming International AIDS Conference will feature a dedicated hub for discussing the deadly duo of TB-HIV.
Dosing of raltegravir when given with rifampicin (post)
WHO (1) recommends that, in resource-limited settings, a first-line antiretroviral treatment (ART) regimen should contain two nucleoside reverse transcriptase inhibitors and a non-nucleoside reverse transcriptase inhibitor (preferably efavirenz in patients on concomitant tuberculosis treatment). Partly because of cost considerations, raltegravir is not included as a first-line option in WHO guidelines and is not widely used in resource-limited settings. In high-income settings, raltegravir is included as an option for first-line regimens (2). Even in resource-limited settings, raltegravir is an attractive option for patients who cannot tolerate efavirenz, and if its price could be reduced it might be used more widely.
In HIV/TB coinfection, raltegravir may be an alternative to efavirenz (post)
Patients coinfected with HIV and tuberculosis (TB) may benefit from raltegravir as an alternative to efavirenz, new research suggests.
Kenyan concerns about rising MDR-TB reflect regional public health challenge (post)
Kenya has made enormous strides in its efforts to tackle tuberculosis amongst its population, improving diagnosis and treatment to such an extent that prevalence has dropped from 335 to 299 cases per 100,000 people between 2006 and 2012. But the continuing insecurity in the region backed by the weakness of the health infrastructure in neighboring countries have maintained the flow of refugees into Kenya, and into the national health system in search of treatment and care.
Page 5 of 52 · Total posts: 0
←First 4 5 6 Last→